- Murray PR, Baron EJ, Pfaller MA, Tenover FC. Yolken RH. Manual of Clinical Microbiology.7th ed.Washington,D.C: ASM Press;1999.p. 517- 525.
- Huang LY, Chen TL, Lu PL, Tsai CA, Cho WL, Chang FY, et al. Dissemination of multidrug-resistant, class 1 integron-carrying Acinetobacter baumannii isolates in Taiwan. Clin Microbiol Infect 2008; 14:1010–1019.
- Nowak-Zaleska A, Krawczyk B, Kotłowski R, Mikucka A, Gospodarek E. Amplification of a single-locus variable-number direct repeats with restriction fragment length polymorphism (DR-PCR/RFLP) for genetic typing of Acinetobacter baumannii strains. Pol J Microbiol 2008; 57:11-17.
- Peleg AY, Seifert H, Paterson DL. Successful Pathogen Acinetobacter baumannii: Emergence of a10.1128/CMR.00058-07. Clin Microbiol Rev2008; 21:538.
- Marais E, G de Jong, Ferraz V, Maloba B, Duse AG.Interhospital transfer of pan-resistant Acinetobacter strains in Johannesburg,South Africa. Am J Infect Control 2004; 32:278–281.
- Merkier AK, Catalano M, Ramírez MS, Quiroga C, Orman B, Ratier L, et al. Polyclonal spread of blaOXA-23 and blaOXA-58 in Acinetobacter baumannii isolates from Argentina. J Infect Dev Ctries 2008; 2:235-240.
- Coelho J, Woodford N, Afzal-Shah M, Livermore D. Occurrence of OXA-58-Like Carbapenemases in Acinetobacter spp. collected over 10 years in three continents. Antimicrob Agents Chemother 2006; 50:756-758.
- Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5:939-951.
- Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933-951.
- 10. Jacoby GA, Munoz-Price LS. Mechanisms of disease the new ß-Lactamases. N Engl J Med 2005; 352:380-3891.
11. Gniadkowski M. Evolution and epidemiology of extended-spectrum b-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001; 7:597–608.
12. Bush k. New beta-lactamases in gram negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32:1085-1089.
13.
Stürenburg E,
Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control.
J Infect 2003; 47:273-295.
- 14. Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, et al. Evolution of extended-spectrum b-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997; 41:647- 653.
17. García-Garmendia JL, Carlos OL, José GM , Francisco-Javier J-J , Carmen P-P, Ana EBA, et al. Risk Factors for Acinetobacter baumannii Nosocomial Bacteremia in Critically Ill Patients :A Cohort Study.Clin Infect Dis 2001;33: 939-946.
18. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PhN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51:3471–3484.
19.
Vahaboglu H,
Oztürk R,
Aygün G,
Coşkunkan F,
Yaman A,
Kaygusuz A,
et al. Wide- spread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial
Acinetobacter and
Pseudomonas aeruginosa isolates in Turkey: A nationwide multi-center study. Antimicrob Agents Chemother 1997; 41:2265–2269.
20.
Yong D,
Shin JH,
Kim S,
Lim Y,
Yum JH,
Lee K,
et al. High prevalence of PER-1 extended-spectrum beta-lactamase-producing
Acinetobacter spp. in Korea. Antimicrob Agents Chemother 2003; 47:1749–1751.
24. Poirel L, Corvec S, Rapoport M, Mugnier P, Petroni A, Pasteran F,
et al. Identification of the novel narrow-spectrum ß-lactamase SCO-1 in Acinetobacter spp. from Argentina.
Antimicrob Agents Chemother 2007; 51:2179-2184.
25.
Gombac F,
Riccio ML,
Rossolini GM,
Lagatolla C,
Tonin E,
Monti-Bragadin C,
et al. Molecular characterization of integrons in epidemiologically unrelated clinical isolates of acinetobacter baumannii from Italian hospitals reveals a limited diversity of gene cassette arrays.Antimicrob Agents Chemother 2002; 46:3665–3668.